Sagard to take Integramed America private in $169.5m deal


Sagard Capital has agreed to buy fertility and vein care specialist Integramed America in a $169.5m take-private deal.

The $14.05 per share offer represents a 24 per cent premium on Friday’s stock price of $11.34, and a 46 per cent premium to the company’s average daily closing price over the past year.

Sagard said the deal was not subject to financing and was expected to close by mid-November.

Integramed provides clinical and business information systems, marketing and sales, and a full suite of HR, legal and fertility treatment financing programmes.

It includes specialty companies Attain Fertility Centers and the Vein Clinics of America.

The firm’s managing partner Dan Freidberg said, “IntegraMed has built a powerful business model anchored by a strong and experienced team of medical, clinical and administrative personnel and by its management and support services.

“They have consistently provided the highest levels of patient care and treatment innovation, while also delivering strong financial performance at above-industry growth rates.

“We look forward to working together with the IntegraMed team and providing the resources and support for the Company’s continued growth and success.”

Copyright © 2012 AltAssets